



Open  Access

Available online at <http://ajprd.com/index.php>

Review Article

FISH MUCUS: A NEGLECTED RESERVOIR FOR ANTIMICROBIAL PEPTIDES

Okella Hedmon^{1*}, Aber Jacqueline¹, Kevin Tindo Koffi³, Kato Charles Drago² and Ogwang Patrick Engeu¹

¹Pharm-Biotechnology and Traditional Medicine center, Department of Pharmacy, Mbarara University of Science and Technology, P.O Box 1410 Mbarara, **Uganda**.

²School of Bio-security, Biotechnical and Laboratory Sciences, College of Veterinary Medicine, Animal Resources and Bio-security, Makerere University, P.O Box 7062, Kampala, **Uganda**

³Biotechnology Engineering Department, V.V.P College of Engineering College, Rajkot, Gujarat, **India**

ABSTRACT:-

Antimicrobial resistance has posed a great global burden, with the fear that by 2050 it would have killed more people than cancer if nothing much is done about it. Alongside several attempts in place, zoo-therapy is becoming one of important remedies in the modern society, with hope for solution believed to be hidden in nature. In this study, the authors present a review of journal articles and reports obtained through key word search of several literature databases on recent developments in the battle against the antimicrobial resistance using fish derived antimicrobial peptides. The findings indicate despite some limitations of these antimicrobial peptides, their very broad spectrum activity against pathogens keeps them among promising antibiotics as far as the battle against multidrug resistance is concerned. Much as various methods to study antimicrobial peptides do exist, fish mucus remains less explored. The study recommends aquatic habitat exploration in search for novel bacterial antimicrobial peptides.

Key words: mucus, peptides, antimicrobial, fish, drug

Article Info: Received 14 July, 2018;

Review Completed 12 Aug 2018;

Accepted 19 Aug 2018;



Cite this article as:

Okella Hedmon, Fish Mucus: A Neglected Reservoir for Antimicrobial Peptides, Asian Journal of Pharmaceutical research and Development.2018;6 (4): 06-11

DOI: <http://dx.doi.org/10.22270/ajprd.v6.i4.389>

*Address for Correspondence

Okella Hedmon, Pharm-Biotechnology and Traditional Medicine center, Department of Pharmacy, Mbarara University of Science and Technology, P.O Box 1410 Mbarara, **Uganda**, E-mail: hedmono @ gmail.com

INTRODUCTION

The contemporary increase in mortality due to bacterial infections has solely been attributed to antimicrobial resistance¹. The potentials of antibiotics to combat bacterial infections have greatly decreased due to the ever increasing multidrug resistance^{2,3}, that claims over 700,000 lives every year⁴, with a projected rise to 10 million by 2050 if alternative solutions are not found⁵. Mortality due to bacterial infections will thus be far worse those caused by malaria which claimed 445,000 lives in 2016⁶, HIV which claims about a million lives annually⁷ and cancers which accounted for 8.8 million deaths in 2015.⁸ At the beginning of 2017, the World Health Organization (WHO) made a desperate global call for new class of

antibiotics⁴. Seven month later (September, 2017), WHO confirms the world is running out of antibiotics and declared a global health emergency that calls for an urgent need for more investment in research and development for antibiotic-resistant infections especially for the ranked 'priority pathogens' that if not watched may within this century, return the world back to the "pre-antibiotic era"⁹. This point out the fact that, the search for novel antimicrobials is cardinal as far as combating the antimicrobial resistance is concerned. In light of the above, four new strategies of overcoming resistance by microbes, are being explored: modifying old antibiotics into entirely new classes, combining antibiotics, supplementing antibiotics with adjuvants or searching nature for novel antibiotics¹⁰. This is in line with the 2010 Infectious Diseases Society of America

(IDSA)'s proposed *10x'20 Global Initiative* aimed at developing 10 new, safe, and effective antibiotics by 2020¹¹. Regrettably, the rate at which these microorganisms develop resistance has outpaced the rate of discovery/development of new class of antibiotics as scientists dig into various ecological niches: marine, plants, animals, soil in search for novel alternatives¹². This study believes, the antimicrobial peptides (AMPs) from the fish mucus could be one of such novel antimicrobials nature can offer, however clear information on their source, recent extraction technologies and utilizability need first to be brought into limelight.

Fish mucus as source of antimicrobial peptides

Fish mucus, a fish by-product, is a cardinal component of fish innate immunity. This mucus constitutes an innate defense barrier of fish skin that continuously prevent stable colonization of majority of infectious microbes such as bacteria, fungus into the fish body¹³. Fish mucus is secreted by epidermal goblet cells and comprises of mucins and other substances such as inorganic salts, immunoglobulin, proteins and lipids suspended in water giving it characteristic lubricating properties¹⁴. The mucus of some fish species like cat. fish of *Claris* spp. have for centuries been used in traditional medicine to heal wounds¹⁵⁻¹⁶, burns¹⁷⁻¹⁸

tumors¹⁸. Their mucus is known for their activity as antibacterial and antifungal agents^{14-15,19-20}. In the Indian traditional medicine, *Anguill abengalensis* (eel fish) has for long been used in treatments of anaemia, burn injury, piles, weakness among other diseases¹⁶ and *Channa striatus* is well known for its wound healing, anti-inflammation, immune-modulatory as well as mild antifungal and antibacterial roles²¹⁻²². These properties have mostly been attributed to the presence of antimicrobial peptides (AMPs), polyunsaturated fatty acids (PUFA), mycosporine-like amino acids (MAAs), organic acids among others¹⁸⁻²¹. Common antimicrobial peptides (Table 1) are secreted both by the fish goblet cells and the skin microbiota they harbor and are known for their broad spectrum activity against parasitic microorganisms at a very low minimum inhibitory concentration (MIC), Epan and Vogel²² emphasized the fact that AMPs are classically known for damaging the cell membrane of pathogenic bacteria. Much as most of them interacts electrostatically with the surface of negatively charged cell membrane, some interacts with the membrane molecules, as others target intracellular molecules²³⁻²⁴. Since they rarely interacts with specific receptors, their microbial targets rarely develops resistant phenotypes²⁴. This has kept a number of peptide antibiotics still standing in the fight against antimicrobial resistance.

Table 1: Common Antimicrobial peptides (AMP) produced by bacteria⁺ and Fish^{*}

Organism	AMP	Sequence	Activity		Reference
			G+	G-	
<i>M. saxatilis</i> *	Piscidin 1	FFHHIFRGIVHVGKTIHRLVTG	+	+	(25)
<i>M. chrysops</i> *	Piscidin 3	FIHHIFRGIVHAGRSIGRFLTG	+	+	(25)
<i>P. americanus</i>	Pleurocidin	GWGSFFKKAHVKGKGVKAALHTYL	+	+	(26)
<i>O. mykiss</i> *	rtCATH_1(R146-P181)	RRSKVRICSRGKNCVSRPGVGSIIIGRPGGSLIGRP		+	(27)
<i>G. morhua</i> *	codCath	SRSGRGSKGGRGSSGSRGSKGPSGSRGSSGSRGSKGSRGGRSGR GSTIAGNGNRNNGGTRTA		+	(28)
	Cod β-defensin	WSCPTLSGVCRKVCLPTMFFGGLGCGKEFQCCVSHFF		+	(29)
<i>C. semilaevis</i> *	CsHEP	LPLDQVQETEGVGMVRGAGMSDTPAAANEETSVDQWITPYHARVKR		+	(30)
<i>L. lactis</i> [†]	Nisin A	IDhb _{cyclo} (AIDhaLA) _{cyclo} (AbuPGA)K _{cyclo} (AbuGALMGA)NMK _{cyclo} (AbuA AbuAHA)SIHVDhaK	+	+	(31)
<i>P. polymyxa</i> [†]	Polymyxin B	(S)-6-Methyloctanoyl-DabTDab- _{cyclo} (DabDab _p FLDabDabT)		+	(32)
	Polymyxin E	(S)-6-Methyloctanoyl-BTB- _{cyclo} (BB D LLBBT)		+	(24)
<i>B. subtilis</i> [†]	Bacitracin A	1-(N-((2-(1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl)carbonyl)LDEI- _{cyclo} (KDOmIDFHDDN)	+	+	(33)
<i>B. brevis</i> [†]	Gramicidin A	CHOVGADLADVVDVWDLWDLWLNHCH2CH2OH	+	+	(34)
	Gramicidin S	_{cyclo} (VOrnLDFP)2	+	+	(35)
	Tyrocidines	_{cyclo} (VOrnLDFPX3/Orn3;K1,2/F1,2L);X(W3NQYVX2DX1)	+	+	(36)

*Pisces; [†]Bacteria G+: Gram+ bacteria; G -: Gram - bacteria; Orn: ornithine; Dhb: didehydroaminobutyric acid; Dha: didehydroalanine; A: animobutidic acid; Dab: diaminobutyric acid.

Methods used in the study of antimicrobial peptides

Different approaches have been employed in the isolation, purification and characterization of AMPs. This has been summarized in the Table 2. Most studies encountered seem to favor direct extraction and batch fermentation for AMPs production. This is justified by the easy of manipulation and the cost since, such can easily be performed in the laboratory without having any effect on the result quality³⁷. A number of the studies on the AMPs are utilized in their crude form³⁸⁻⁴⁰.

This is this partly as a result of high cost and tediousness of the purification process. However, it limits the applicability and potency of the AMPs due to high level of contaminants, leaving Reverse Phase High Performance Liquid Chromatography (RP-HPLC) as an extremely valuable tool as AMPs are generally resistant to different organic solvents used in mobile phase and to the pressure employed through the chromatographic process³⁹.

Table 2: Methods commonly used in the study of AMPs

AMPs source (skin mucus and symbiotants)	Purification	Characterization	Reference
<i>Channapunctatus</i>	Precipitation	Disc diffusion assay	(19)
<i>Clariasbatrachus</i> and <i>Tilapia mossambicus</i> ,	Precipitation	SDS-PAGE	(40)
Frog	Precipitation RP-HPLC	SDS-PAGE MALDI-TOF	(41)
Spiny eel	Precipitation	UV Spectrophotometer SDS-PAGE GC/MS	(42)
Hag fish	Precipitation RP-HPLC	Protein-dye binding Electro blotting Edman degradation SDS-PAGE Nano electrospray MS BLAST FPLC	(43)
<i>Bacillus sp.</i>	RPC RP-HPLC C ₁₈ -LC	SDS-PAGE LC-MS/MS SEM	(2)
Hag fish	RPC	SDS-PAGE	(44)
<i>Aerobacillus species</i> SAT4	Precipitation Gel permeation RP-HPLC	UV Spectrophotometer SDS-PAGE FTIR NMR XRD	(45)
<i>Gadusmorhua</i>	Precipitation HPLC	SDS-PAGE MALDI MS BLAST	(46)
<i>Lactobacillus plantrum</i>	Precipitation Ion exchange RP-HPLC AA analyzer	SDS-PAGE IR UV MS	(39)
<i>Aeribacillus sp.</i>	Precipitation GPC RP-HPLC	SDS-PAGE FTIR XRD	(45)
<i>Cynoglossusarel</i> and <i>Arius caelatus</i>	Precipitation	FTIR Immunomodulation	(47)

UV-Ultraviolet, GC- Gas chromatography, SEM- Scanning Electron Microscopy, IR- Infrared, MS- Mass spectrometry, SDS-PAGE- sodium dodecyl sulphate polyacrylamide gel electrophoresis, FTIR- Fourier Transform Infrared, NMR- Nuclear Magnetic Resonance, MALDI-TOF- Matrix assisted laser desorption ionization Time-of-flight, LC- Liquid chromatography, XRD- X-ray diffraction, HPLC- Reverse Phase High Performance Liquid Chromatography

Elucidation of the structure of AMPs is vital as far as understanding their utilization potentials is concerned. To elucidate the structure, the knowledge about the primary amino acid sequence is paramount. Amino acid analyzer connected to a RP-HPLC have been reported by several studies as an effective tool in amino acid

analysis³⁹. However, this can only reveal the percentage composition of the amino acids in a protein not the sequence², hence a matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF/MS), is commonly used for protein sequence revelation due to its speed, sensitivity and specificity⁴³.

Although Further, Nuclear Magnetic Resonance Spectroscopy (NMR) and X-Ray crystallography are the most important tools as far as determining high resolution structural information of AMPs is concerned. However, protein interactions protein size gaps and conformational flexibility limit their use in AMPs studies⁴⁸. This explain why most studies on AMPs adopt combination of Fourier-Transform Infrared (FTIR) and NMR spectroscopy to reveal 2 dimensional structures of AMPs from which bioinformatics tools may be employed to obtain the three dimension structure⁴⁵

Limitations in utilization of antimicrobial peptides

AMPs are known for their high sensitivity to pH, temperature and enzymes, this hinders their production and utilization because of their they are protein in nature and can easily be denatured during the process³⁷. Further, their small size and limited number of amino acids limits the structure elucidation of the AMPs. This limited information on the structure of AMPs based on the primary amino acid sequences has jeopardized functional pharmacological approach to dose-response assessments of AMPs and their susceptibility to target cell membrane⁴⁹. Conversely, with the contemporary advancement in bioinformatics, this hold-back of the AMPs have been extinguished²⁴. AMPs with limited number of rare and D-amino acids are highly vulnerable to protease activity thereby reducing their bioavailability⁵⁰ as well as alternative routes of administration⁵¹ and has enabled *S. aureus* gain a substantial resistance against dermicidin⁵² yet some have poor penetration of AMPs through the intestinal mucosa when taken orally and implicated toxic.

Summary of the review findings

In this review, the following facts were established about the antimicrobial peptides.

Broad spectrum activity

The review has reveals the vast activity of the antimicrobial peptides against both the gram positive and gram negative bacteria, an activity not common to the conventional standard antibiotics like penicillin and Chloramphenicol. This ability to overcome resistance as

highlighted earlier due to the AMPs multiple target sides and non-specific mode of action.

Diversity of study approaches

Several methods to study the AMPs do exist. However, the small size of AMPs together with protein interactions and conformational flexibility limit the study of AMPs. To this effect, combinations of recent technologically advanced approaches have been engaged so as to explore various AMPs from different habitats.

Paying AMPs limitation debt

Low stability of AMPs during production into pharmaceutical forms, toxicity and poor pharmacokinetics jeopardize their utilization. However, structurally altering AMPs⁵³ and functional pharmacological approach to dose-response assessments of AMPs prior to production²⁴ are some of the suggested ways to reduce toxicity. Further, the poor pharmacokinetics, especially poor oral bioavailability; short plasma half-lives among others may be overcome by increasing the number of rare amino acids during AMPs synthesis and production alongside analogue synthesis⁵⁰. Lastly, incorporation of D-amino acids that are stable in the presence of protease⁵⁴ and synergism of AMPs with standard antibiotics⁵⁵ can increase their stability.

Conclusion and future perspective

Much as AMPs show broad antimicrobial activity especially those isolated from marine habitat using recent technologies, other habitats such as fresh water fish mucus remain less explored.

Conflict of interests

The authors have do declare no conflict of interests.

Acknowledgement

The authors acknowledge the support from Pharm Biotechnology and Traditional Medicine Center (PHARMBIOTRAC), Mbarara University of Science and Technology and Government of Uganda.

REFERENCES

- Martens E, Demain AL. The antibiotic resistance crisis , with a focus on the United States. J Antibiot (Tokyo) [Internet]. 2017;2017(January):1–7. Available from: <http://dx.doi.org/10.1038/ja.2017.30>
- Xin H, Ji S, Peng J, Han P, An X, Wang S, et al. Isolation and characterisation of a novel antibacterial peptide from a native swine intestinal tract-derived bacterium. Int J Antimicrob Agents [Internet]. 2017; Available from: <http://dx.doi.org/10.1016/j.ijantimicag.2016.12.012>
- Tillotson GS, Zinner SH. Burden of antimicrobial resistance in an era of decreasing susceptibility. Expert Rev Anti Infect Ther [Internet]. 2017;15(7):663–76. Available from: <https://doi.org/10.1080/14787210.2017.1337508>
- WHO. Drug-resistant bacteria ranked. Nature. 2017 Mar;15.
- O'Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. London; 2014.
- WHO. World malaria report 2017. Geneva; 2017.
- WHO. WHO Global Health Observatory data 2017. Geneva; 2017.
- WHO. World Cancer Report 2016. Geneva; 2016.
- WHO. Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva; 2017.
- The Scientist. Overcoming Resistance. LabX Media Group [Internet]. 2014 Apr;1–10. Available from: <https://www.the-scientist.com/?articles.view/articleNo/39512/title/Overcoming-Resistance/>
- IDSA. The 10X'20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020. Clin Infect Dis. 2010;50(8):1081–3.
- Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2(31):1–13.
- Vennila R, Kumar KR, Kanchana S, Arumugam M, Vijayalakshmi S. Preliminary investigation on antimicrobial

- and proteolytic property of the epidermal mucus secretion of marine stingrays. *Asian Pac J Trop Biomed* [Internet]. 2011;1(2):S239–43. Available from: [http://dx.doi.org/10.1016/S2221-1691\(11\)60162-7](http://dx.doi.org/10.1016/S2221-1691(11)60162-7)
14. Tyor AK, Kumari S. Biochemical characterization and antibacterial properties of fish skin mucus of fresh water fish, *hypophthalmichthys nobilis*. *Int J Pharm Pharm Sci*. 2016;8(6):6–10.
 15. Chinwuba T, Okafor SN, Okechukwu DC. Catfish (*Clarias gariepinus*) Slime Coat Possesses Antimicrobial and Wound Healing Activities. *UK Journal of Pharmaceutical and Biosciences*. 2016;4(3):84–7.
 16. Rahman S, Choudhury JK, Dutta A, Kalita MC. Eel Ichthyofauna of Assam in Folklore Therapeutic Practices. *Int J Interdiscip Multidiscip Stud*. 2014;1(5):273–6.
 17. Blakeslee S. Catfish Slime – TM's Healing Agents. *The New York Times*. 1988 Jan 26;C00003.
 18. Deslouches B, Di YP. Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. *Oncotarget*. 2017;8(28):46635–51.
 19. Nwabueze AA, Campus A, Campus A. Antimicrobial Action of Epidermal Mucus Extract of *Clarias gariepinus* (Burchell , 1822) Juveniles-Fed Ginger Inclusion in Diet. *Int J Biol*. 2014;6(2):42–8.
 20. Loganathan K, Muniyan M, Prakash AA, Raja PS, Prakash M. Studies on the role of mucus from *clarias batrachus* (Linn) against studies on the role of mucus from *clarias batrachus* (Linn) against selected microbes. *Int J Pharm Appl ISSN*. 2014;2(3):202–6.
 21. Wei ONGY, Xavier R, Marimuthu K. Screening of antibacterial activity of mucus extract of Snakehead fish , *Channa striatus* (Bloch). *Eur Rev Med Pharmacol Sci*. 2010;675–81.
 22. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. *Biochem Biophys Acta*. 1999;1462:11–28.
 23. Hancock RE. Review Cationic peptides : effectors in innate immunity and novel antimicrobials. *Infect Dis (Auckl)*. 2001;1(October):156–64.
 24. Ageitos JM, Villa TG. Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria. *Biochem Pharmacol* [Internet]. 2016; Available from: <http://dx.doi.org/10.1016/j.bcp.2016.09.018>
 25. Jackson GS, Beck JA, Sutton PM, Contreras M, Collinge J. Peptide antibiotics in mast cells of fish. *Nature* [Internet]. 2001 Dec;414(November):268–70. Available from: www.nature.com
 26. Cole AM, Weis P, Diamond G. Isolation and Characterization of Pleurocidin , an Antimicrobial Peptide in the Skin Secretions of Winter Flounder *. *J Biol Chem*. 1997;272(18):12008–13.
 27. Chang C, Zhang Y, Zou J, Nie P, Secombes CJ. Two Cathelicidin Genes Are Present in both Rainbow Trout (*Oncorhynchus mykiss*) and Atlantic Salmon (*Salmo salar*). *Antimicrob Agents Chemother*. 2006;50(January):185–95.
 28. Broekman DC, Zenz A, Gudmundsdottir BK, Lohner K, Maier VH, Gudmundsson GH. Peptides Functional characterization of codCath , the mature cathelicidin antimicrobial peptide from Atlantic cod (*Gadus morhua*). *Peptides* [Internet]. 2011;32(10):2044–51. Available from: <http://dx.doi.org/10.1016/j.peptides.2011.09.012>
 29. Ruangsri J, Kitani Y, Kiron V, Lokesh J, Brinchmann MF, Karlsen O, et al. A Novel Beta-Defensin Antimicrobial Peptide in Atlantic Cod with Stimulatory Effect on Phagocytic Activity. *PLoS One*. 2013;8(4).
 30. Masso-silva JA, Diamond G. Antimicrobial Peptides from Fish. *Pharmaceuticals*. 2014;7:265–310.
 31. Rogers LA. The inhibiting effect of streptococcus lactis on lactobacillus bulgaricus. *J Bacteriol*. 1928;16(5):321–5.
 32. Bahar AA, Ren D. Antimicrobial Peptides. *Pharmaceuticals*. 2013;6:1543–75.
 33. Ikai Y, Oka H, Hayakawa J, Matsumoto M. Total Structures and Antimicrobial Activity of Bacitracin Minor Components. *J Antibiot (Tokyo)*. 1994;48(3):233–42.
 34. Townsley LE, Tucker WA, Sham S, Hinton JF. Structures of Gramicidins A , B , and C Incorporated into Sodium Dodecyl Sulfate. *Biochemistry*. 2001;15:11676–86.
 35. Bzmka T. Properties of synthetic analogs of gramicidin S containing L-serine or L-glutamic acid residue in place of L-ornithine residue. *Int J Pept Protein Res*. 1996;47:369–75.
 36. Dubos JR. Studies on a Bactericidal Agent Extracted from a Soil Bacillus: I. Preparation of the Agent. Its Activity in Vitro. *J Exp Med*. 1939;70(1939):1–10.
 37. Eid R, J EJ, Rashidy A, Asfour H, Omara S, Mm K, et al. Probiotics & Health Potential Antimicrobial Activities of Probiotic Lactobacillus Strains Isolated from Raw Milk. *J Probiotics Heal*. 2016;4(2):2–9.
 38. Sankar NR, Priyanka VD, Reddy PS, Rajanikanth P, Kumar VK, Indira M. Purification and Characterization of Bacteriocin Produced by Lactobacillus plantarum Isolated from Cow Milk. *Int J Microbiol Res*. 2012;3(2):133–7.
 39. Atta HM, Refaat BM. Application of Biotechnology for Production , Purification and Characterization of Peptide Antibiotic Produced by Probiotic Lactobacillus plantarum , NRRL B-227. *Glob J Biotechnol Biochem*. 2009;4(2):115–25.
 40. Elavarasi K, Ranjini S, Rajagopal T. Bactericidal proteins of skin mucus and skin extracts from fresh water fishes , *Clarias batrachus* and *Tilapia mossambicus* Abstract : *Thai J Pharm Sci*. 2013;37:194–200.
 41. Koehbach J, Gruber CW, Becker C, Kreil DP, Jilek A. MALDI TOF/TOF-Based Approach for the Identification of. 2016;
 42. Uthayakumar V, Ramasubramanian V, Senthilkumar D. Biochemical characterization , antimicrobial and hemolytic studies on skin mucus of fresh water spiny eel *Mastacembelus armatus*. *Asian Pac J Trop Biomed* [Internet]. 2012;2(2):S863–9. Available from: [http://dx.doi.org/10.1016/S2221-1691\(12\)60325-6](http://dx.doi.org/10.1016/S2221-1691(12)60325-6)
 43. Subramanian S, Ross NW, Mackinnon SL. Myxinidin , A Novel Antimicrobial Peptide from the Epidermal Mucus of Hagfish , *Myxine glutinosa* L . *Mar Biotechnol*. 2009;11:748–57.
 44. Subramanian S, Ross NW, Mackinnon SL. Comparison of antimicrobial activity in the epidermal mucus extracts of fish. *Comp Biochem Physiol*. 2008;150:85–92.
 45. Syed AM, Sifa A. Production and characterization of a new antibacterial peptide obtained from *Aeribacillus pallidus* SAT4. *Biotechnol Reports*. 2015;8:72–80.
 46. Bergsson G, Agerberth B, Jo H. Isolation and identification of antimicrobial components from the epidermal mucus of Atlantic cod (*Gadus morhua*). *FEBBS J*. 2005;272:4960–9.
 47. Bragadeeswaran S, Priyadarshini S, Prabhu K, Raj S, Rani S. Antimicrobial and hemolytic activity of fish epidermal mucus *Cynoglossus arel* and *Arius caelatus*. *Asian Pac J Trop Med* [Internet]. 2011;4(4):305–9. Available from: [http://dx.doi.org/10.1016/S1995-7645\(11\)60091-6](http://dx.doi.org/10.1016/S1995-7645(11)60091-6)
 48. Mendoza VL, Vachet RW. Probing Protein Structure by Amino Acid-Specific Covalent Labeling and Mass Spectrometry. *Mass spectrom*. 2010;28(5):785–815.
 49. Cherkasov A, Hilpert K, Fjell CD, Waldbrook M, Mullaly SC, Volkmer R, et al. Use of Artificial Intelligence in the Design of Small Peptide Antibiotics Effective against a Broad Spectrum of Highly Antibiotic-Resistant Superbugs. *ACS Chem Biol*. 2009;4(1):65–74.
 50. Czyzewski AM, Jenssen H, Fjell CD, Waldbrook M, Barron E. In Vivo , In Vitro , and In Silico Characterization of Peptoids as Antimicrobial Agents. *PLoS One*. 2016;1–17.
 51. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. *Front Cell Infect Microbiol*. 2016;6(December):1–12.

52. Lai Y, Villaruz AE, Li M, Cha DJ, Sturdevant DE, Otto M. The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in staphylococci. *Mol Microbiol.* 2006;63(December 2006):497–506.
53. Wilcox S. The New Antimicrobials : Cationic Peptides. *BioTech J.* 2004;2(Fall 2014):88–91.
54. Wade D, Bomant A, Wxhlint B, Drain CM, Andreut D, Bomant HG, et al. All-D amino acid-containing channel-forming antibiotic peptides. *Biochemistry.* 1990;87(June):4761–5.
55. Wu X, Li Z, Li X, Tian Y, Fan Y, Yu C, et al. Synergistic effects of antimicrobial peptide DP7 combined with antibiotics against multidrug- resistant bacteria. *Drug Des Devel Ther.* 2017;11:939–46.

